The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer.
OBJECTIVE
Polysaccharide K (PSK) is widely used in Japan as a biological response modifier for cancer patients. We investigated the effects of PSK with S-1 based chemotherapy for advanced gastric cancer patients in immune response.


METHODS
Nine advanced gastric cancer patients who underwent chemotherapy at the University of Tokushima were included in this study. In all patients, 3g PSK was received orally and S-1 based chemotherapy for 2 weeks alternately for 8 weeks. Serial changes in immunological parameters (Foxp3, Natural killer (NK), CD4/CD8) were monitored.


RESULTS
The levels of Foxp3 at 8 weeks was significantly decreased compared with 2 weeks (4.26% vs. 3.11%). In NK activity at 8 weeks was significantly increased compared with 2 weeks (27% vs. 47%).


CONCLUSIONS
These results of this study suggested that chemotherapy with PSK improved the immune response in advanced gastric cancer patients. Especially Foxp3 was concerned in this mechanism.
Kozo
K
Yoshikawa
Mitsuo
M
Shimada
Nobuhiro
N
Kurita
Hirohiko
H
Sato
Takashi
T
Iwata
Masanori
M
Nishioka
Shinya
S
Morimoto
Tomohiko
T
Miyatani
Masato
M
Komatsu
R Nhideya Kashihara
RN
And
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D011509:Proteoglycans / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000276:immunology; D005641:Tegafur / Q000008:administration & dosage
D004338:Drug Combinations; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D011509:Proteoglycans; C079198:S 1 (combination); D005641:Tegafur; C010770:polysaccharide-K; D010094:Oxonic Acid